287 related articles for article (PubMed ID: 23127473)
1. Positron emission tomography/computed tomography imaging in Merkel cell carcinoma: a study of 270 scans in 97 patients at the Dana-Farber/Brigham and Women's Cancer Center.
Hawryluk EB; O'Regan KN; Sheehy N; Guo Y; Dorosario A; Sakellis CG; Jacene HA; Wang LC
J Am Acad Dermatol; 2013 Apr; 68(4):592-599. PubMed ID: 23127473
[TBL] [Abstract][Full Text] [Related]
2. The impact of (18)F-FDG-PET/CT on Merkel cell carcinoma management: a retrospective study of 66 scans from a single institution.
George A; Girault S; Testard A; Delva R; Soulié P; Couturier OF; Morel O
Nucl Med Commun; 2014 Mar; 35(3):282-90. PubMed ID: 24240193
[TBL] [Abstract][Full Text] [Related]
3. Merkel cell carcinoma: Is there a role for 2-deoxy-2-[f-18]fluoro-D-glucose-positron emission tomography/computed tomography?
Iagaru A; Quon A; McDougall IR; Gambhir SS
Mol Imaging Biol; 2006; 8(4):212-7. PubMed ID: 16724293
[TBL] [Abstract][Full Text] [Related]
4. 18F-fluorodeoxyglucose positron emission tomography-computed tomography imaging in the management of Merkel cell carcinoma: a single-institution retrospective study.
Ibrahim SF; Ahronowitz I; McCalmont TH; Hernandez Pampaloni M; Ryan JL; Yu SS
Dermatol Surg; 2013 Sep; 39(9):1323-33. PubMed ID: 23777452
[TBL] [Abstract][Full Text] [Related]
5. The impact of (18)F-FDG PET-CT scanning for staging and management of Merkel cell carcinoma: results from Westmead Hospital, Sydney, Australia.
Concannon R; Larcos GS; Veness M
J Am Acad Dermatol; 2010 Jan; 62(1):76-84. PubMed ID: 20082888
[TBL] [Abstract][Full Text] [Related]
6. Lack of clinical impact of
Liu J; Larcos G; Howle J; Veness M
Australas J Dermatol; 2017 May; 58(2):99-105. PubMed ID: 26459330
[TBL] [Abstract][Full Text] [Related]
7. Comparison of 18F-FDG PET/CT and 111In pentetreotide scan for detection of Merkel cell carcinoma.
Lu Y; Fleming SE; Fields RC; Coit DG; Carrasquillo JA
Clin Nucl Med; 2012 Aug; 37(8):759-62. PubMed ID: 22785503
[TBL] [Abstract][Full Text] [Related]
8. 15-Year Experience of 18F-FDG PET Imaging in Response Assessment and Restaging After Definitive Treatment of Merkel Cell Carcinoma.
Byrne K; Siva S; Chait L; Callahan J; Bressel M; Seel M; MacManus MP; Hicks RJ
J Nucl Med; 2015 Sep; 56(9):1328-33. PubMed ID: 26159592
[TBL] [Abstract][Full Text] [Related]
9. Comparison of (18)F-FDG PET/CT and (68)Ga-DOTATATE PET/CT imaging in metastasized Merkel cell carcinoma.
Epstude M; Tornquist K; Riklin C; di Lenardo F; Winterhalder R; Hug U; Strobel K
Clin Nucl Med; 2013 Apr; 38(4):283-4. PubMed ID: 23429397
[TBL] [Abstract][Full Text] [Related]
10. Metabolic assessment of Merkel cell carcinoma: the role of 18F-FDG PET/CT.
Ben-Haim S; Garkaby J; Primashvili N; Goshen E; Shapira R; Davidson T; Israel O; Epelbaum R
Nucl Med Commun; 2016 Aug; 37(8):865-73. PubMed ID: 27092665
[TBL] [Abstract][Full Text] [Related]
11. Somatostatin receptor positron emission tomography/computed tomography imaging in Merkel cell carcinoma.
Sollini M; Taralli S; Milella M; Erba PA; Rubagotti S; Fraternali A; Roncali M; Moscarella E; Perotti G; Rufini V; Versari A
J Eur Acad Dermatol Venereol; 2016 Sep; 30(9):1507-11. PubMed ID: 26446694
[TBL] [Abstract][Full Text] [Related]
12. Merkel cell carcinoma: two case reports focusing on the role of fluorodeoxyglucose positron emission tomography imaging in staging and surveillance.
Yao M; Smith RB; Hoffman HT; Funk GF; Graham MM; Buatti JM
Am J Clin Oncol; 2005 Apr; 28(2):205-10. PubMed ID: 15803018
[TBL] [Abstract][Full Text] [Related]
13. 18F-FDG PET provides high-impact and powerful prognostic stratification in the staging of Merkel cell carcinoma: a 15-year institutional experience.
Siva S; Byrne K; Seel M; Bressel M; Jacobs D; Callahan J; Laing J; Macmanus MP; Hicks RJ
J Nucl Med; 2013 Aug; 54(8):1223-9. PubMed ID: 23753187
[TBL] [Abstract][Full Text] [Related]
14. Discordant findings in patients with non-small-cell lung cancer: absolutely normal bone scans versus disseminated bone metastases on positron-emission tomography/computed tomography.
Ak I; Sivrikoz MC; Entok E; Vardareli E
Eur J Cardiothorac Surg; 2010 Apr; 37(4):792-6. PubMed ID: 20015657
[TBL] [Abstract][Full Text] [Related]
15. The utility of positron emission tomography with and without computed tomography in patients with nonmelanoma skin cancer.
Duncan JR; Carr D; Kaffenberger BH
J Am Acad Dermatol; 2016 Jul; 75(1):186-96. PubMed ID: 26992283
[TBL] [Abstract][Full Text] [Related]
16. Baseline ultrasound and FDG-PET/CT imaging in Merkel cell carcinoma.
Zijlker LP; Bakker M; van der Hiel B; Bruining A; Klop WMC; Zuur CL; Wouters MWJM; van Akkooi ACJ
J Surg Oncol; 2023 Apr; 127(5):841-847. PubMed ID: 36573839
[TBL] [Abstract][Full Text] [Related]
17. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
[TBL] [Abstract][Full Text] [Related]
18. Bone marrow 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma.
Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
Am J Hematol; 2014 Jul; 89(7):726-31. PubMed ID: 24711255
[TBL] [Abstract][Full Text] [Related]
19. Restaging [
Mahajan S; Barker CA; Mauguen A; Singh B; Pandit-Taskar N
J Am Acad Dermatol; 2020 Apr; 82(4):878-886. PubMed ID: 31562942
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of (18)F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study.
Caobelli F; Alongi P; Evangelista L; Picchio M; Saladini G; Rensi M; Geatti O; Castello A; Laghai I; Popescu CE; Dolci C; Crivellaro C; Seghezzi S; Kirienko M; De Biasi V; Cocciolillo F; Quartuccio N;
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):404-13. PubMed ID: 26381775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
